RxDoctor Payments Data

Laura Galindo, NP

Family · Folsom, CANPI 1043789159

Payments from drug & device makers

$715in general payments, 2019–2025

Across 21 payments — averaging $34.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$321
  • Johnson & Johnson$123
  • Ipsen Biopharmaceuticals, Inc$52
  • Corcept Therapeutics$44
  • Exact Sciences$44
  • Sobi, Inc$30
  • plus $101 from 4 others

What the payments were for

  • Food & beverage$52874%
  • Education$18726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$715 in reported general payments places this provider in the 65th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$101,765
Medicare patients
128
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IdhifaEnasidenib Mesylate22$725,305
JakafiRuxolitinib Phosphate41$533,312
Lenalidomide15$201,802
CresembaIsavuconazonium Sulfate21$124,075
VenclextaVenetoclax16$95,980
PrevymisLetermovir12$85,441
Posaconazole38$48,847
Atovaquone54$23,738
EliquisApixaban27$15,126
Voriconazole13$5,080
Acyclovir133$3,868
Tacrolimus20$2,446
Midodrine Hcl18$610
Levothyroxine Sodium51$560
Fluconazole14$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$321$533,31241 claims
MerckPrevymis$25$85,44112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,634 family providers in California.

Other family in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →